Omeros Corp (OMER.OQ)

OMER.OQ

About

Omeros Corporation operates as a biopharmaceutical company focused on the discovery, development and commercialization of products focused on inflammation and disorders of the central nervous system. The Company develops pharmaceutical and therapeutic approaches to the management of surgical pain and inflammation, vasospasm,... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	0.72
Market Cap (Mil.):	$151.45
Shares Outstanding (Mil.):	29.81
Dividend:	--
Yield (%):	--

Financials

	OMER.OQ	Industry	Sector
P/E (TTM):	--	43.62	34.28
EPS (TTM):	-1.60	--	--
ROI:	-846.92	1.67	18.85
ROE:	--	2.94	19.72

Latest News about OMER.OQ

Omeros' knee surgery drug fails in late-stage study

- Omeros Corp said a late-stage trial of its experimental drug for patients undergoing knee surgery did not meet its main goal, sending the company's shares down as much as 10 percent in extended trade.

27 Dec 2012

» More OMER.OQ News

Competitors

	Price	Change
Pfizer Inc. (PFE.N)	$29.04	-0.07
Johnson & Johnson (JNJ.N)	$86.82	-0.39
Novartis AG (NOVN.VX)	CHF71.25	-0.20
Merck & Co., Inc. (MRK.N)	$47.16	-0.17
Roche Holding Ltd. (ROG.VX)	CHF253.10	+2.40
Abbott Laboratories (ABT.N)	$37.76	+0.28
Bayer AG (BAYGn.DE)	€84.46	+0.55
Bayer AG (BAYE.F)	--	--
Sanofi SA (SASY.PA)	€84.51	-0.30
Eli Lilly & Co. (LLY.N)	$54.14	-0.60

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Thomson Reuters Stock Report - OMEROS CORPORATION (OMER-O) Provider: Thomson Reuters Stock Report	$25.00 Buy
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of OMEROS CORP including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. Provider: Jefferson Research	$20.00 Buy
ValuEngine Detailed Valuation Report for OMER Provider: ValuEngine, Inc.	$127.00 Buy
Omeros Corporation (OMER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Provider: GlobalData	$250.00 Buy
OMEROS CORP (OMER) Zacks Company Snapshot Provider: Zacks Investment Research Inc.	$12.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.